WASHINGTON (March 31, 2014) — Patients given aspirin to prevent heart problems after non-heart-related surgery had a higher risk of serious bleeding than the patients who did not receive aspirin. At the same time, aspirin did not reduce incidence of post-operative heart attacks and death, according to data from POISE-2 presented at the American College of Cardiology's 63rd Annual Scientific Session. POISE-2 is the largest clinical trial focused on major cardiovascular complications in non-cardiac surgery.
Although many guidelines address prophylactic aspirin in a surgical setting, the focus is largely on cardiac surgery. Little guidance is available for patients undergoing non-cardiac surgery. This phase III trial followed earlier evidence suggesting that small doses of aspirin and clonidine can ward off heart attacks and heart-related death for such patients. Data for clonidine are to be presented separately at ACC.14.
POISE-2 enrolled 10,011 patients in 23 countries and grouped them by aspirin use: those who had been taking any dose daily for four of the six weeks before surgery, which became the continuation stratum, and those who had not, the initiation stratum. For the continuation stratum, aspirin use was stopped at least 72 hours before surgery. All patients received placebo or 200 mg aspirin just before surgery. The initiation stratum continued 100 mg aspirin or placebo daily for 30 days. The continuation stratum received 100 mg aspirin or placebo for seven days and then resumed their previous aspirin regimen. The primary endpoint of death and non-fatal heart attack at 30 days was no different between the two groups (7 percent in the aspirin group and 7.1 percent in the placebo group); however, major bleeding was significantly higher in aspirin-treated patients than in the placebo group (4.6 percent vs. 3.7 percent). The primary and secondary outcomes were similar in the two aspirin strata.
"POISE-2 demonstrated that adding aspirin on top of prophylactic anticoagulants in patients who are having non-cardiac surgery is not beneficial," said P.J. Devereaux, M.D., Ph.D., associate professor of clinical epidemiology and biostatistics at McMaster University, and lead investigator for the study. "An important caveat is that 65 percent of our patients were on prophylactic anticoagulants."
There is strong evidence that aspirin prevents perioperative blood clots in veins if an anticoagulant isn't given, he noted. No subgroup effects were seen for vascular versus non-vascular surgery or baseline risk according to the Revised Cardiac Risk Index.
With major bleeding known to increase the likelihood of post-surgical heart attack and a post-hoc POISE-2 regression analysis demonstrating this relationship, researchers considered why their study found a higher risk for bleeding but not for heart attack. "One possibility is that aspirin did prevent some heart attacks, but we were causing enough bleeding to nullify that benefit," Devereaux said. The study used clinical measurements for maximum reliability in identifying heart attacks, because symptoms are masked by pain-killing drugs in more than 50 percent of patients who have heart attacks after surgery.
According to data analysis, the absolute risk increase for life-threatening and major bleeding with aspirin treatment drops from about 1.2 percent on the day of surgery to 0.9 percent by day four and to 0.3 by day eight. At about the eighth day, the risk returns to normal. This information will help doctors weigh benefits versus potential risks when aspirin might be indicated post-surgically, Devereaux said.
"We're confirming a finding that bleeding itself can cause heart attacks," he said. "We need to find a better way to prevent bleeding so we can get back to how to prevent some of these thrombotic events." Patients will be followed for a year, and one-year data will be analyzed.
Although POISE-2 is a large trial by perioperative standards, the lower (0.86) and upper (1.15) boundary of the hazard ratio for the primary outcome identifies that the possibility of appreciable benefit or harm has not been excluded, Devereaux said.
POISE-2 was funded through grants from the Canadian Institutes of Health Research, the Commonwealth Government of Australia's National Health and Medical Research Council and the Spanish Ministry of Health and Social Policy. Bayer Pharma AG provided the aspirin study drug, and Boehringer Ingelheim provided the clonidine study drug and some funding.
This study and the clonidine results from POISE-2 will be simultaneously published online in the New England Journal of Medicine at the time of presentation.
The ACC's Annual Scientific Session brings together cardiologists and cardiovascular specialists from around the world each year to share the newest discoveries in treatment and prevention. Follow @ACCMediaCenter and #ACC14 for the latest news from the meeting.
The American College of Cardiology is a nonprofit medical society comprised of 47,000 physicians, surgeons, nurses, physician assistants, pharmacists and practice managers. The College is dedicated to transforming cardiovascular care, improving heart health and advancing quality improvement, patient-centered care, payment innovation and professionalism. The ACC also leads the formulation of important cardiovascular health policy, standards and guidelines. It bestows credentials upon cardiovascular specialists, provides professional education, supports and disseminates cardiovascular research, and operates national registries to measure and promote quality care. For more information, visit CardioSource.org.
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.